Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:44 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 735 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Biliary Diseases Clear all

Conditions: Primary Sclerosing Cholangitis
Interventions: Anti-human CCL24 monoclonal antibody (CM-101), Placebo; Biological · Other
Lead sponsor: ChemomAb Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 8
States / cities: La Jolla, California • Sacramento, California • Chicago, Illinois + 4 more

Conditions: Cholecystitis
Interventions: Stryker1688 Fluorescence imaging system; Device
Lead sponsor: Stryker Endoscopy; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Annapolis, Maryland

Conditions: Primary Sclerosing Cholangitis, Biliary Atresia
Interventions: Oral Vancomycin; Drug
Lead sponsor: Sacramento Pediatric Gastroenterology; Other
Eligibility: 2 Weeks to 40 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2028
U.S. locations: 1
States / cities: Sacramento, California

Conditions: HER2-amplified Biliary Tract Cancers
Interventions: ZW25 (Zanidatamab); Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 14
States / cities: Gilbert, Arizona • Tucson, Arizona • Duarte, California + 11 more

Conditions: Cancer
Interventions: Fentanyl sublingual spray, Placebo; Drug
Lead sponsor: INSYS Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Chandler, Arizona

Conditions: Primary Biliary Cholangitis
Interventions: Cilofexor, Placebo to match cilofexor; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 13
States / cities: Sacramento, California • Aurora, Colorado • Lakewood Rch, Florida + 9 more

Conditions: Stage III Intrahepatic Cholangiocarcinoma AJCC v7, Stage IIIA Gallbladder Cancer AJCC v7, Stage IIIB Gallbladder Cancer AJCC v7, Stage IVA Gallbladder Cancer AJCC v7, Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7, Stage IVB Gallbladder Cancer AJCC v7, Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7, Unresectable Extrahepatic Bile Duct Carcinoma, Unresectable Gallbladder Carcinoma
Interventions: Cisplatin, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Nab-paclitaxel; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 3
States / cities: Scottsdale, Arizona • Rochester, Minnesota • Houston, Texas

Conditions: Intraoperative Bleeding, Liver Diseases, Gallbladder Diseases, Hemorrhage, Surgical
Interventions: GATT-Patch, SURGICEL® Original; Device
Lead sponsor: GATT Technologies BV; Industry
Eligibility: 22 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 6
States / cities: Los Angeles, California • St Louis, Missouri • Pennington, New Jersey + 3 more

Conditions: Disorders of the Pancreas and Biliary Tree
Interventions: ERCP as per medical indication; Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2015
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Colorectal Cancer, Gastro Esophageal Junctional Cancer, Gastric Cancer (GC), GEJ Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC), Gall Bladder Cancer, Cholangiocarcinoma
Interventions: IKS04 antibody drug conjugate ADC + Isumab04 monoclonal antibody; Drug
Lead sponsor: Iksuda Therapeutics Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 4
States / cities: Los Angeles, California • Boston, Massachusetts • Nashville, Tennessee + 1 more

Conditions: Primary Biliary Cirrhosis
Interventions: Combination antiviral therapy, Placebo; Drug
Lead sponsor: University of Alberta; Other
Eligibility: 18 Years to 75 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 2
States / cities: Rochester, Minnesota • St Louis, Missouri

Conditions: Biliary Tract Cancer (BTC)
Interventions: D07001-Softgel Capsules, Placebo, Capecitabine; Drug · Combination Product
Lead sponsor: InnoPharmax Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 4
States / cities: Tucson, Arizona • Miami Beach, Florida • Cleveland, Ohio + 1 more

Conditions: Pregnancy Complications, Acute Appendicitis, Acute Cholecystitis, Biliary Pancreatitis, Bowel Obstruction, Acute Diverticulitis
Interventions: non-obstetric acute general surgical disease; Procedure
Lead sponsor: Methodist Health System; Other
Eligibility: 18 Years and older · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Choledocholithiasis, Bile Duct Diseases, Bile Duct Carcinoma
Interventions: "Air" contrast cholangiography using carbon dioxide gas; Other
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Primary Biliary Cholangitis
Interventions: CNP-104, Placebo; Drug
Lead sponsor: COUR Pharmaceutical Development Company, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 19
States / cities: Coronado, California • Lancaster, California • Sacramento, California + 16 more

Conditions: Primary Sclerosing Cholangitis, Liver Transplant, Complications, PSC, Biliary Strictures
Interventions: Fenofibrate (drug), Blood draw for the laboratory assessment, MRI using a hepatobiliary phase contrast agent (Gd-EOB-DPTA); Drug · Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Total Parenteral Nutrition-induced Cholestasis
Interventions: Omegaven, Omegaven; Dietary Supplement · Drug
Lead sponsor: Pediatrix; Other
Eligibility: 14 Days to 2 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Biliary Tract Cancer
Interventions: Gemcitabine, Cisplatin, Durvalumab, Trastuzumab deruxtecan, Rilvegostomig; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 620 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 48
States / cities: Scottsdale, Arizona • Tucson, Arizona • Fullerton, California + 38 more

Conditions: Primary Biliary Cirrhosis
Interventions: Moexipril; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Cholestasis, Liver Disease
Interventions: Omegaven IV; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 1 Day to 5 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Staten Island, New York

Conditions: KRAS G12D Mutation, Advanced Solid Cancer
Interventions: ARV-806; Drug
Lead sponsor: Arvinas Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 14
States / cities: Phoenix, Arizona • New Haven, Connecticut • Tampa, Florida + 9 more

Conditions: Biliary Atresia
Interventions: Maralixibat, Placebo; Drug · Other
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: 21 Days to 111 Days
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 7
States / cities: Phoenix, Arizona • Atlanta, Georgia • New York, New York + 3 more

Conditions: Cholecystitis
Interventions: Injection of indocyanine green (ICG), Near Infrared Cholangiography Fluorescence (NIRF-C); Drug · Device
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Recurrent Colon Cancer, Liver Metastases, Stage IV Rectal Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer
Interventions: floxuridine, leucovorin calcium, melphalan; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: Not listed
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

CM-101 in PSC Patients -The SPRING Study

SPY Fluorescence Imaging Systems and Indocyanine Green to Determine the Percentage of Successful Critical Anatomy Recognition in Laparoscopic Cholecystectomy Surgeries.

Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin

A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis

Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers

GATT-Patch Versus SURGICEL® Original in Minimally Invasive Liver and Gallbladder Surgery

The Clinical Utility of Cholangioscopy and Pancreatoscopy in the Diagnosis and Management of Pancreaticobiliary Disorders

IKS04 Regimen in Advanced Solid Tumors That Express CA242

Study of Combivir for Patients With Primary Biliary Cirrhosis

D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer

Fetal Outcomes Among Pregnant Emergency General Surgery Patients

Cholangiography Using Carbon Dioxide Versus Iodinated Contrast in ERCP

Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis

Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation

Intravenous Fat Emulsion Comprised of Fish Oil in the Treatment of Parenteral Nutrition Induced Liver Injury in Infants

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

Moexipril for Primary Biliary Cirrhosis

Compassionate Use of Omegaven IV Fat Emulsion

A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation

Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai

Near Infrared Fluorescence Cholangiography (NIRF-C) During Cholecystectomy

Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver